12 / 22
conferenceseries LLC Ltd
Notes:
Page 43
Clinical Pharmacology & Biopharmaceutics | ISSN : 2167-065X
Volume 7
September 18-19, 2018 | Amsterdam, Netherlands
6
th
European Biopharma Congress
Euro Biopharma 2018
Essential considerations for selecting clinical research organizations (cross): Pragmatic guidance for biotech companies
based on case-studies in Europe, Japan, and the US
Hiroko Tadano
Trans World Clinical Alliance, Netherlands
S
enior management in biotechnology organizations span the gamut of industry expertise from deep academic and research backgrounds
to corporate, global biopharma skills, and everything else in between. This internal collective corporate experience and history often
drives how a clinical research organization (CRO) partners are eventually selected, and often without considerations to other key imperative
elements that determine the best fit, for the immediate as well as the long-term needs of a clinical development program. The presenters will
utilize case-study examples from biotechnology companies in Europe, Japan, and the US to describe how biotechnology companies can
increase their chances of success in choosing an appropriate external clinical development partner. Understanding where blind-spots often
occur, how to navigate internal corporate mind-sets, and individual biases will be discussed through case-examples. Various approaches and
solutions will be highlighted, and specifically tailored for the small- to mid-size biotechnology companies. The presenters will also discuss
critical issues in the selection process such as fees, deliverables, timelines, and managing disappointments.
hs@lumisinternational.comClin Pharmacol Biopharm 2018, Volume:7
DOI: 10.4172/2167-065X-C1-029